447 related articles for article (PubMed ID: 32092967)
21. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
[TBL] [Abstract][Full Text] [Related]
22. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
[TBL] [Abstract][Full Text] [Related]
23. Altered iron metabolism in cystic fibrosis macrophages: the impact of CFTR modulators and implications for Pseudomonas aeruginosa survival.
Hazlett HF; Hampton TH; Aridgides DS; Armstrong DA; Dessaint JA; Mellinger DL; Nymon AB; Ashare A
Sci Rep; 2020 Jul; 10(1):10935. PubMed ID: 32616918
[TBL] [Abstract][Full Text] [Related]
24. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK
mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.
Cheng PC; Alexiou S; Rubenstein RC
Expert Rev Respir Med; 2019 May; 13(5):417-423. PubMed ID: 30929526
[TBL] [Abstract][Full Text] [Related]
26. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
[TBL] [Abstract][Full Text] [Related]
27. Orkambi® and amplifier co-therapy improves function from a rare
Molinski SV; Ahmadi S; Ip W; Ouyang H; Villella A; Miller JP; Lee PS; Kulleperuma K; Du K; Di Paola M; Eckford PD; Laselva O; Huan LJ; Wellhauser L; Li E; Ray PN; Pomès R; Moraes TJ; Gonska T; Ratjen F; Bear CE
EMBO Mol Med; 2017 Sep; 9(9):1224-1243. PubMed ID: 28667089
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
29. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease.
Mancini G; Loberto N; Olioso D; Dechecchi MC; Cabrini G; Mauri L; Bassi R; Schiumarini D; Chiricozzi E; Lippi G; Pesce E; Sonnino S; Pedemonte N; Tamanini A; Aureli M
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599772
[TBL] [Abstract][Full Text] [Related]
30. Quorum Sensing Down-Regulation Counteracts the Negative Impact of
Maillé É; Ruffin M; Adam D; Messaoud H; Lafayette SL; McKay G; Nguyen D; Brochiero E
Front Cell Infect Microbiol; 2017; 7():470. PubMed ID: 29177135
[TBL] [Abstract][Full Text] [Related]
31. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
[TBL] [Abstract][Full Text] [Related]
32. Cigarette smoke activates CFTR through ROS-stimulated cAMP signaling in human bronchial epithelial cells.
Wong FH; AbuArish A; Matthes E; Turner MJ; Greene LE; Cloutier A; Robert R; Thomas DY; Cosa G; Cantin AM; Hanrahan JW
Am J Physiol Cell Physiol; 2018 Jan; 314(1):C118-C134. PubMed ID: 28978522
[TBL] [Abstract][Full Text] [Related]
33. Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants.
Laselva O; Bartlett C; Popa A; Ouyang H; Gunawardena TNA; Gonska T; Moraes TJ; Bear CE
J Cyst Fibros; 2021 Jan; 20(1):106-119. PubMed ID: 32741662
[TBL] [Abstract][Full Text] [Related]
34. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
35. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
36. The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
Hammond JA; Connett GJ
Paediatr Respir Rev; 2018 Jun; 27():16-17. PubMed ID: 29914743
[TBL] [Abstract][Full Text] [Related]
37. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
38. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
[TBL] [Abstract][Full Text] [Related]
40. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
Connett GJ
Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
